{"disease":{"id":"acute-myeloid-leukemia-myelodysplastic-syndromes","name":"acute myeloid leukemia myelodysplastic syndromes"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03904134","title":"Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1753,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT04060485","title":"Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04093570","title":"A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":332,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT04986657","title":"Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS","phase":"NA","overall_status":"RECRUITING","enrollment_count":325,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03310918","title":"A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":320,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06001385","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT04771130","title":"A Study of BGB-11417 in Participants With Myeloid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT05991908","title":"Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":222,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05150561","title":"Muscle Dysfunction in Patients With Haematological Diseases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":216,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT00309842","title":"Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT05875805","title":"A Telehealth Advance Care Planning Intervention","phase":"NA","overall_status":"RECRUITING","enrollment_count":207,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT07319793","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05641259","title":"A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":198,"lead_sponsor_name":"Guangzhou Lupeng Pharmaceutical Company LTD.","has_results":false},{"nct_id":"NCT04232241","title":"Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":167,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT04609826","title":"A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06475820","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT04167683","title":"Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":144,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT00045942","title":"PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07183878","title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","phase":"NA","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT05140811","title":"A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":126,"lead_sponsor_name":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","has_results":false},{"nct_id":"NCT02488408","title":"A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"BerGenBio ASA","has_results":true},{"nct_id":"NCT06046313","title":"Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT03852407","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":114,"lead_sponsor_name":"University of Liege","has_results":false},{"nct_id":"NCT05275439","title":"Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":106,"lead_sponsor_name":"Shattuck Labs, Inc.","has_results":true},{"nct_id":"NCT04202003","title":"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04275518","title":"A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT07449286","title":"IFN-α in Relapse Prevention.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT02743351","title":"Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Fate Therapeutics","has_results":true},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02223052","title":"Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT03927261","title":"PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"Precigen, Inc","has_results":false},{"nct_id":"NCT04263181","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT00008177","title":"Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03849651","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT04358393","title":"A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT00255346","title":"Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06536959","title":"VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT05961839","title":"Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Schrödinger, Inc.","has_results":false},{"nct_id":"NCT01211457","title":"Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":65,"lead_sponsor_name":"Cyclacel Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT00629798","title":"Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT07238712","title":"Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT06439199","title":"Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06050941","title":"Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT01869114","title":"Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT04402541","title":"Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Cleave Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03560882","title":"A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Joaquina Baranda","has_results":false},{"nct_id":"NCT04943757","title":"Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT06299462","title":"PTCy and ATG for MSD and MUD Transplants","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Instituto Nacional de Cancer, Brazil","has_results":false},{"nct_id":"NCT04024761","title":"A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}